JP2021527671A - インスリン抵抗性及び代謝疾患の軽減又は治療のための組成物及び方法 - Google Patents

インスリン抵抗性及び代謝疾患の軽減又は治療のための組成物及び方法 Download PDF

Info

Publication number
JP2021527671A
JP2021527671A JP2020570747A JP2020570747A JP2021527671A JP 2021527671 A JP2021527671 A JP 2021527671A JP 2020570747 A JP2020570747 A JP 2020570747A JP 2020570747 A JP2020570747 A JP 2020570747A JP 2021527671 A JP2021527671 A JP 2021527671A
Authority
JP
Japan
Prior art keywords
amino acid
composition
acid entity
entity
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020570747A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021527671A5 (https=
JPWO2019246299A5 (https=
Inventor
ハミル，マイケル
アフェイェン，ラフィ
リー，チュン−ウェイ
ルトハルト，ハリー
コーム，ウィリアム
ダウ，ナディン
マルキアン，スヴェトラーナ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Axcella Health Inc
Original Assignee
Axcella Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axcella Health Inc filed Critical Axcella Health Inc
Publication of JP2021527671A publication Critical patent/JP2021527671A/ja
Publication of JP2021527671A5 publication Critical patent/JP2021527671A5/ja
Publication of JPWO2019246299A5 publication Critical patent/JPWO2019246299A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2020570747A 2018-06-20 2019-06-19 インスリン抵抗性及び代謝疾患の軽減又は治療のための組成物及び方法 Pending JP2021527671A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862687727P 2018-06-20 2018-06-20
US62/687,727 2018-06-20
US201962794134P 2019-01-18 2019-01-18
US62/794,134 2019-01-18
PCT/US2019/038037 WO2019246299A1 (en) 2018-06-20 2019-06-19 Compositions and methods for the reduction or treatment of insulin resistance and metabolic conditions

Publications (3)

Publication Number Publication Date
JP2021527671A true JP2021527671A (ja) 2021-10-14
JP2021527671A5 JP2021527671A5 (https=) 2022-09-08
JPWO2019246299A5 JPWO2019246299A5 (https=) 2022-09-08

Family

ID=67185732

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020570747A Pending JP2021527671A (ja) 2018-06-20 2019-06-19 インスリン抵抗性及び代謝疾患の軽減又は治療のための組成物及び方法

Country Status (6)

Country Link
US (2) US20210275479A1 (https=)
EP (1) EP3810122A1 (https=)
JP (1) JP2021527671A (https=)
CN (1) CN112689508A (https=)
MA (1) MA52953A (https=)
WO (1) WO2019246299A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
CN112823018A (zh) 2018-06-20 2021-05-18 胺细拉健康公司 制备氨基酸组合物的方法
CN111514276B (zh) * 2020-06-29 2021-07-27 黑龙江中医药大学 短肽Asp-His-Tyr在制备治疗多囊卵巢综合征的药物中的应用
WO2022266480A1 (en) * 2021-06-17 2022-12-22 Axcella Health Inc. Methods of predicting liver fat content and uses thereof
WO2023009444A1 (en) 2021-07-26 2023-02-02 Axcella Health Inc. Amino acid compositions and methods for use in the treatment of post-acute sequelae of covid-19
EP4643658A1 (en) * 2024-04-29 2025-11-05 Laboratorios Ern S.A. Dietary product for hypoproteic diet
CN119679774A (zh) * 2024-11-15 2025-03-25 北京体育大学 预防或治疗代谢性疾病的药物及应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1557301A (zh) * 2004-01-15 2004-12-29 高春平 降低老年肥胖型糖尿病人血糖和血脂的组合物
US20050233014A1 (en) * 2004-03-02 2005-10-20 Lee Steve S Methods for affecting homeostasis and metabolism in a mammalian body

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ20022927A3 (cs) * 2000-02-01 2003-06-18 Muscletech Research And Development Inc. Doplňky stravy založené na alfa-lipoové kyselině pro zvýšení čisté svalové hmoty a síly
US20050176827A1 (en) * 2002-05-10 2005-08-11 Lee Steve S. Compositions and methods for glycogen synthesis

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1557301A (zh) * 2004-01-15 2004-12-29 高春平 降低老年肥胖型糖尿病人血糖和血脂的组合物
US20050233014A1 (en) * 2004-03-02 2005-10-20 Lee Steve S Methods for affecting homeostasis and metabolism in a mammalian body

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 508, JPN6023015673, 2005, pages 205 - 210, ISSN: 0005200875 *
JOURNAL OF ENDOCRINOLOGY, vol. 225, JPN6023015672, 2015, pages 1 - 7, ISSN: 0005200874 *

Also Published As

Publication number Publication date
US20240238232A1 (en) 2024-07-18
US20210275479A1 (en) 2021-09-09
MA52953A (fr) 2021-04-28
CN112689508A (zh) 2021-04-20
EP3810122A1 (en) 2021-04-28
WO2019246299A1 (en) 2019-12-26

Similar Documents

Publication Publication Date Title
US11602511B2 (en) Amino acid compositions and methods for the treatment of liver diseases
US20240238232A1 (en) Compositions and methods for the reduction or treatment of insulin resistance and metabolic conditions
KR20200039748A (ko) 간 질환 치료를 위한 아미노산 조성물
US20110077198A1 (en) Compositions and methods for inhibiting the activation of dsrna-dependent protein kinase and tumor growth inhibition
JP2021529736A (ja) 炎症の軽減又は治療のための組成物及び方法
TW202015667A (zh) 治療血色素異常及地中海型貧血之組合物及方法
JP2018517782A (ja) 相乗的飲料組成物
US20210275480A1 (en) Compositions and methods for the reduction or treatment of fibrosis
Mykkänen Bilberries in health and obesity-Wild nature fruits of blueberries (Vaccinium myrtillus) alter obesity associated transcriptomics and low-grade inflammation
EP4260849A1 (en) Compound for the reduction of white adipose tissue and the treatment of overweight and obesity
CN119421706A (zh) 用于预防和/或治疗肠病的包含氨基酸的组合物
OA19827A (en) Amino acid compositions and methods for the treatment of liver diseases.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220620

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220620

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220826

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230425

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20231121